Neurocrine Biosciences Stock Price, News & Analysis (NASDAQ:NBIX)

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) released its quarterly earnings results on Monday, July, 29th. The company reported $0.37 earnings per share for the quarter, topping analysts' consensus estimates of $0.24 by $0.13. The firm earned $183.58 million during the quarter, compared to the consensus estimate of $161.79 million. Neurocrine Biosciences had a return on equity of 0.46% and a net margin of 2.98%. The business's revenue was up 89.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.07) EPS. View Neurocrine Biosciences' Earnings History.

Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Neurocrine Biosciences.

Neurocrine Biosciences will be holding an earnings conference call on Monday, November 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

19 brokerages have issued 1-year price objectives for Neurocrine Biosciences' stock. Their forecasts range from $84.00 to $135.00. On average, they expect Neurocrine Biosciences' stock price to reach $106.56 in the next twelve months. This suggests a possible upside of 11.3% from the stock's current price. View Analyst Price Targets for Neurocrine Biosciences.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 3 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurocrine Biosciences.

Media coverage about NBIX stock has trended somewhat positive recently, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Neurocrine Biosciences earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Neurocrine Biosciences.

Neurocrine Biosciences saw a decline in short interest in the month of September. As of September 30th, there was short interest totalling 3,530,000 shares, a decline of 7.6% from the August 30th total of 3,820,000 shares. Based on an average daily trading volume, of 674,100 shares, the days-to-cover ratio is presently 5.2 days. Approximately 3.9% of the shares of the company are sold short. View Neurocrine Biosciences' Current Options Chain.

Some companies that are related to Neurocrine Biosciences include Seattle Genetics (SGEN), NOVOZYMES A/S/S (NVZMY), BIO-TECHNE (TECH), Qiagen (QGEN), bluebird bio (BLUE), Moderna (MRNA), China Biologic Products (CBPO), argenx (ARGX), Repligen (RGEN), Spark Therapeutics (ONCE), Adaptive Biotechnologies (ADPT), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA) and Halozyme Therapeutics (HALO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Gilead Sciences (GILD), AbbVie (ABBV), Netflix (NFLX), Celgene (CELG), Exelixis (EXEL), Sarepta Therapeutics (SRPT) and ACADIA Pharmaceuticals (ACAD).

Neurocrine Biosciences' stock is owned by many different of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.16%), Envestnet Asset Management Inc. (0.04%), Assenagon Asset Management S.A. (0.03%), Mission Wealth Management LP (0.01%), Nisa Investment Advisors LLC (0.01%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Neurocrine Biosciences stock include Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops, Stephen A Sherwin and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences.

NBIX stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Mission Wealth Management LP, Oakbrook Investments LLC and Fox Run Management L.L.C.. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Darin Lippoldt, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy and Richard F Pops. View Insider Buying and Selling for Neurocrine Biosciences.

NBIX stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Meeder Asset Management Inc., Envestnet Asset Management Inc., OmniStar Financial Group Inc., Heritage Investors Management Corp, Stephens Inc. AR, Zurcher Kantonalbank Zurich Cantonalbank and Nisa Investment Advisors LLC. View Insider Buying and Selling for Neurocrine Biosciences.

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NBIX stock can currently be purchased for approximately $95.78.

Neurocrine Biosciences has a market capitalization of $8.77 billion and generates $451.24 million in revenue each year. The company earns $21.11 million in net income (profit) each year or $0.22 on an earnings per share basis. Neurocrine Biosciences employs 585 workers across the globe.View Additional Information About Neurocrine Biosciences.

The official website for Neurocrine Biosciences is http://www.neurocrine.com/.

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]